<DOC>
	<DOCNO>NCT00019864</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy surgery may shrink tumor remove surgery . Giving chemotherapy surgery may kill tumor cell . PURPOSE : This phase II trial study well give chemotherapy surgery work treat patient osteosarcoma .</brief_summary>
	<brief_title>Combination Chemotherapy Before After Surgery Treating Patients With Osteosarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine rate vivo histologic response patient osteosarcoma treat neoadjuvant cisplatin , methotrexate , doxorubicin dexrazoxane ( cardioprotection ) . - Determine event-free overall survival patient nonmetastatic disease show good response neoadjuvant therapy receive adjuvant therapy regimen . - Determine event-free survival patient nonmetastatic disease show poor response neoadjuvant therapy receive adjuvant therapy regimen . - Determine event-free survival overall survival patient metastatic disease receive neoadjuvant therapy . OUTLINE : This multicenter study . - Neoadjuvant therapy : Patients receive neoadjuvant chemotherapy comprise dexrazoxane IV 15 minute , doxorubicin IV 15 minute , cisplatin IV 4 hour day 1 2 week 0 . Patients also receive methotrexate IV 4 hour follow leucovorin calcium week 3 4 . Patients receive filgrastim ( G-CSF ) subcutaneously ( SC ) daily begin 24 hour completion chemotherapy continue blood count recover . Treatment repeat every 5 week 2 course absence disease progression unacceptable toxicity . - Surgical resection : Patients undergo definitive surgery week 11 . - Adjuvant therapy : Patients receive dexrazoxane , doxorubicin , cisplatin , methotrexate , leucovorin calcium neoadjuvant therapy* . Treatment repeat every 5 week 4 course absence disease progression unacceptable toxicity . NOTE : *Cisplatin administer course 3 4 adjuvant therapy Patients follow within 4 week , every 3 month 2 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : Approximately 100 patient accrue study .</detailed_description>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Cardiotoxicity</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Dexrazoxane</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Razoxane</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm newly diagnose osteosarcoma No 1 month since prior diagnostic biopsy Nonmetastatic malignant highgrade osteosarcoma bone Histologically confirm metastatic disease allow Unresectable primary disease allow No lowgrade , parosteal , periosteal osteosarcoma PATIENT CHARACTERISTICS : Age : 25 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8.0 g/dL Hepatic : Bilirubin great 2.0 mg/dL ALT le 5 time normal Renal : Creatinine great 1.5 time normal Creatinine clearance radioisotope glomerular filtration rate great 70 mL/min Cardiovascular : Shortening fraction least 27 % echocardiogram MUGA Ejection fraction least 45 % echocardiogram MUGA Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception 6 month study PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : No concurrent therapy evidence progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>cardiac toxicity</keyword>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>recurrent osteosarcoma</keyword>
</DOC>